New contrast agents for imaging the liver

Magnetic Resonance Imaging Clinics of North America

Volumn 9, Issue 4, 2001, Pages 745-766

  Helmberger, T ^a   Semelka, R C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; ECHOVIST; FERUCARBOTRAN; FLUORODEOXYGLUCOSE F 18; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOMELITOL; GADOMER 17; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; MANGAFODIPIR; NSR 0430; SBPA; SHU 555; SUPERPARAMAGNETIC IRON OXIDE; TRACER; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; ECHOGRAPHY; HEMANGIOMA; KUPFFER CELL; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER METASTASIS; RETICULOENDOTHELIAL SYSTEM; REVIEW;

EID: 0035149928     PISSN: 10649689     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1064-9689(21)00272-5     Document Type: Review

References (83)

1. Enhanced tumor detection in the presence of liver cirrhosis: Experimental study on the diagnostic value of a superparamagnetic iron oxide MR imaging contrast agent (NSR 0430)
2. Detection of focal hepatic lesions: Comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP
3. Liver metastases: Safety and efficacy of detection with superpara-magnetic iron oxide in MR imaging
4. Comparison of Gd-EOB-DTPA and Gd-DTPA for contrast-enhanced MR imaging of liver tumors
5. Benign and malignant hepatocellular tumors: Evaluation of tumoral enhancement after mangafodipir trisodium injection on MR imaging
6. Hepatic tumors: Detection and characterization at 1-T MR imaging enhanced with AMI-25
7. Superparamagnetic iron oxide: Detection of focal liver lesions at high-field-strength MR imaging
8. New MR imaging contrast agents
9. Hepatic arterial-phase dynamic gadolinium-enhanced MR imaging: Optimization with a test examination and a power injector
10. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the U.S. Multicenter Phase III Clinical Trials. Efficacy of early imaging
11. The uptake of Mn-DPDP by hepatocytes is not mediated by the facilitated transport of pyridoxine
12. Pancreatic enhancement after low-dose infusion of Mn-DPDP
13. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg)
14. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration
15. Biodistribution and in vivo stability of manganese dipyridoxyl diphosphate in relation to imaging efficacy
16. MR lymphography with superparamagnetic iron nanoparticles in rats: Pathologic basis for contrast enhancement
17. Liver-specific MR imaging contrast agents
18. Clinical utility and safety of MultiHance in magnetic resonance imaging of liver cancer: Results of multicenter studies in Europe and the USA
19. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics, and MR imaging
20. Comparison of dual-phase helical CT with native and ferum oxide-enhanced magnetic resonance imaging in detection and characterization of focal liver lesions
21. Unenhanced, Gd-DTPA-, and ferumoxides-enhanced MRI in focal hepatic disease: A comparison in over 900 patients
22. MR imaging in the evaluation of hepatic metastases
23. MnDPDP-enhanced MR imaging of the liver. Correlation with surgical findings
24. Dose-dependency and rate of decay of efficacy of Resovist on MR images in a rat cirrhotic liver model
25. Experimental hepatic dysfunction: Evaluation by MRI with Gd-EOB-DTPA
26. Gadobenate dimeglumine (Gd-BOPTA). An overview
27. Clinical late phase II trials of MultiHance (Gd-BOPTA) for the magnetic resonance imaging of liver tumors in Japan
28. Liver-specific contrast media: A magic bullet or a weapon for dedicated targets?
29. General toxicology of MnDPDP
30. Hypervascular malignant liver lesions: Comparison of various MR imaging pulse sequences and dynamic CT
31. CT and MR imaging of the liver using liver-specific contrast media. A comparative study in a tumour model
32. Detection of colorectal liver metastases: Prospective comparison of unenhanced and ferumoxides-enhanced magnetic resonance imaging at 1.5 T, dual-phase spiral CT, and spiral CT during arterial portography
33. Delayed MR imaging of hepatocellular carcinoma enhanced by gadobenate dimeglumine (Gd-BOPTA)
34. Gadobenate dimeglumine (BOPTA) enhanced MR imaging: Patterns of enhancement in normal liver and cirrhosis
35. Comparison between Gd-DTPA, Gd-EOB-DTPA, and Mn-DPDP in induced HCC in rats: A correlation study of MR imaging, microangiography, and histology
36. Unexpected MR-T 1 enhancement of endocrine liver metastases with mangafodipir
37. MRI in focal liver disease: A comparison of small and ultra-small superparamagnetic iron oxide as hepatic contrast agents
38. Ring enhancement in ultrasmall superparamagnetic iron oxide MR imaging: A potential new sign for characterization of liver lesions
39. Mangafodipir trisodium: Effects on T2- and T1-weighted MR cholangiography
40. Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophages
41. Cirrhosis of the liver: MR imaging with mangafodipir trisodium (Mn-DPDP)
42. MR imaging evaluation of liver enhancement by Gd-EOB-DTPA in selective and total bile duct obstruction in rats: Correlation with serologic, microcholangiographic, and histologic findings
43. Hepatic lesions: Detection with ferumoxide-enhanced T1-weighted MR imaging
44. Focal liver lesions: Evaluation of the efficacy of gadobenate dimeglumine in MR imaging-a multicenter phase III clinical study
45. Contrast-enhanced 3D-MRA of the upper abdomen with a bolus-injectable SPIO (SH U 555 A)
46. T1 effects of a bolus-injectable superparamagnetic iron oxide, SH U 555 A: Dependence on field strength and plasma concentration-preliminary clinical experience with dynamic T1-weighted MR imaging
47. Phase II clinical evaluation of Gd-EOB-DTPA: Dose, safety aspects, and pulse sequence
48. Hepatic MRI with SPIO: Detection and characterization of focal liver lesions
49. Asialoglyco-protein receptor function in benign liver disease: Evaluation with MR imaging
50. Metal ion release from paramagnetic chelates: What is tolerable?
51. Hepatocellular tumors: Characterization with Mn-DPDP-enhanced MR imaging
52. Hepatic MR imaging with ferumoxides: A multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions
53. MnDPDP for MR imaging of the liver. Results of an independent image evaluation of the European phase III studies
54. A comparison of two MR hepatobiliary gadolinium chelates: Gd-BOPTA and Gd-EOB-DTPA
55. Safety of approved MR contrast media for intravenous injection
56. Update: Safety, new applications, new MR agents
57. Occlusive and reperfused myocardial infarcts: Differentiation with Mn- DPDP-enhanced MR imaging
58. Multicentre doseranging study on the efficacy of USPIO ferumoxtran-10 for liver MR imaging
59. Detection of experimental hepatic tumors using long circulating superparamagnetic particles
60. Pharmacokinetics of the liver-specific contrast agent Gd-EOB-DTPA in relation to contrast-enhanced liver imaging in humans
61. Contrast agents for MR imaging of the liver
62. Malignant liver lesions: Comparison of spiral CT arteriel portography and MR imaging for diagnostic accuracy, cost, and effect on patient management
63. Liver lesion detection, characterization, and effect on patient management: Comparison of single-phase spiral CT and current MR techniques
64. Detection of hepatic metastases: Ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography
65. Safety profile of ultrasmall superparamagnetic iron oxide ferumoxtran-10: Phase II clinical trial data
66. Dual contrast enhancement of both T1- and T2-weighted sequences using ultrasmall superparamagnetic iron oxide
67. Will ferumoxides-enhanced MR imaging replace CT during arterial portography in the detection of hepatic metastases? Prologue to a promising future
68. Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: Results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers
69. Dynamic MR imaging of liver metastases with Gd-EOB-DTPA
70. Pathomorphological study of Kupffer cells in hepatocellular carcinoma and hyperplastic nodular lesions in the liver
71. Detection of hepatocellular carcinoma arising in cirrhotic livers: Comparison of gadolinium- and ferumoxides-enhanced MR imaging
72. Evaluation of gadobenate dimeglumine in hepatocellular carcinoma: Results from phase II and phase III clinical trials in Japan
73. Performance of Gd-EOB-DTPA and superparamagnetic iron oxide particles in the detection of primary liver cancer: A comparative study by alternative free-response receiver operating characteristic analysis
74. MnDPDP for MR imaging of the liver. Results from the European phase III studies
75. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency
76. Preclinical profile of Gd-BOPTA. A liver-specific MRI contrast agent
77. Liver tumors: Comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA
78. Hepatocellular carcinoma: Evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation
79. Uptake of mangafodipir trisodium in liver metastases from endocrine tumors
80. Hepatocellular carcinoma in the cirrhotic liver: Double-contrast MR imaging for diagnosis
81. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI
82. Ul-trasmall superparamagnetic iron oxide: Characterization of a new class of contrast agents for MR imaging
83. Dynamic breath-hold multiplanar spoiled gradient-recalled MR imaging with gadolinium enhancement for differentiating hepatic hemangiomas from malignancies at 1.5 T